Create Free Account

By creating account you will get access to hot stocks & personalised emails

Zoetis Inc

Healthcare US ZTS

164.035USD
-2.975(1.78%)

Last update at 2024-12-19T18:55:00Z

Day Range

163.41167.44
LowHigh

52 Week Range

140.24201.92
LowHigh

Fundamentals

  • Previous Close 167.01
  • Market Cap90399.54M
  • Volume1515078
  • P/E Ratio40.18
  • Dividend Yield0.88%
  • EBITDA3473.00M
  • Revenue TTM8371.00M
  • Revenue Per Share TTM18.09
  • Gross Profit TTM 5634.00M
  • Diluted EPS TTM4.90

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 2656.00M 2488.00M 1996.00M 1801.00M 1690.00M
Minority interest 3.00M -3.00000M -2.00000M 4.00M -4.00000M
Net income 2114.00M 2037.00M 1638.00M 1500.00M 1428.00M
Selling general administrative 2009.00M 2001.00M 1726.00M 1638.00M 1484.00M
Selling and marketing expenses - - - - -
Gross profit 5626.00M 5473.00M 4618.00M 4268.00M 3914.00M
Reconciled depreciation 465.00M 161.00M 441.00M 412.00M 308.00M
Ebit 2888.00M 2755.00M 2288.00M 2075.00M 1964.00M
Ebitda 3038.00M 2916.00M 2729.00M 2230.00M 2081.00M
Depreciation and amortization 150.00M 161.00M 441.00M 155.00M 117.00M
Non operating income net other -40.00000M -48.00000M -17.00000M 57.00M 83.00M
Operating income 2888.00M 2755.00M 2288.00M 2075.00M 1881.00M
Other operating expenses 5152.00M 4973.00M 4406.00M 4242.00M 3944.00M
Interest expense 221.00M 224.00M 231.00M 223.00M 206.00M
Tax provision 545.00M 454.00M 360.00M 301.00M 266.00M
Interest income 50.00M 6.00M 12.00M 37.00M 31.00M
Net interest income -171.00000M -224.00000M -219.00000M -186.00000M -175.00000M
Extraordinary items - - - - 45.00M
Non recurring 11.00M 43.00M 25.00M 51.00M 68.00M
Other items - - - - -
Income tax expense 545.00M 454.00M 360.00M 301.00M 266.00M
Total revenue 8080.00M 7776.00M 6675.00M 6260.00M 5825.00M
Total operating expenses 2698.00M 2670.00M 2349.00M 2250.00M 2033.00M
Cost of revenue 2454.00M 2303.00M 2057.00M 1992.00M 1911.00M
Total other income expense net -232.00000M -267.00000M -292.00000M -274.00000M 15.00M
Discontinued operations - - - - -
Net income from continuing ops 2111.00M 2034.00M 1636.00M 1500.00M 1424.00M
Net income applicable to common shares 2114.00M 2037.00M 1638.00M 1500.00M 1428.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14925.00M 13900.00M 13609.00M 11545.00M 10777.00M
Intangible assets 1380.00M 1474.00M 1710.00M 1890.00M 2046.00M
Earning assets - - - - -
Other current assets 365.00M 389.00M 366.00M 318.00M 271.00M
Total liab 10522.00M 9356.00M 9836.00M 8837.00M 8592.00M
Total stockholder equity 4405.00M 4543.00M 3769.00M 2708.00M 2185.00M
Deferred long term liab 142.00M 320.00M 378.00M 434.00M 474.00M
Other current liab 1410.00M 1361.00M 93.00M 55.00M 866.00M
Common stock 5.00M 5.00M 5.00M 5.00M 5.00M
Capital stock 5.00M 5.00M 5.00M 5.00M 5.00M
Retained earnings 8668.00M 7186.00M 5659.00M 4427.00M 3270.00M
Other liab 585.00M 811.00M 891.00M 917.00M 926.00M
Good will 2746.00M 2682.00M 2694.00M 2592.00M 2519.00M
Other assets 320.00M 211.00M 392.00M 160.00M 147.00M
Cash 3577.00M 3482.00M 3602.00M 1932.00M 1602.00M
Cash and equivalents 3577.00M 3482.00M 3602.00M 1932.00M 1602.00M
Total current liabilities 3167.00M 1797.00M 2170.00M 1806.00M 1223.00M
Current deferred revenue - - 1016.00M 950.00M 35.00M
Net debt 4513.00M 3261.00M 3760.00M 4679.00M 4850.00M
Short term debt 1352.00M 0.00000M 604.00M 500.00M 9.00M
Short long term debt 1352.00M - 604.00M 500.00M 9.00M
Short long term debt total 8090.00M 6743.00M 7362.00M 6611.00M 6452.00M
Other stockholder equity -3451.00000M -1884.00000M -1165.00000M -998.00000M -461.00000M
Property plant equipment 2753.00M 2422.00M 2202.00M 1940.00M 1658.00M
Total current assets 7506.00M 6930.00M 6611.00M 4748.00M 4399.00M
Long term investments - - - 26.00M 8.00M
Net tangible assets 279.00M 387.00M -635.00000M -1774.00000M -2357.00000M
Short term investments - - - 0.00000M 99.00M
Net receivables 1215.00M 1133.00M 1013.00M 1086.00M 1036.00M
Long term debt 6552.00M 6592.00M 6595.00M 5947.00M 6443.00M
Inventory 2345.00M 1923.00M 1628.00M 1410.00M 1391.00M
Accounts payable 405.00M 436.00M 457.00M 301.00M 313.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity -2.00000M 1.00M 4.00M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -817.00000M -764.00000M -730.00000M -726.00000M -629.00000M
Additional paid in capital - - - - -
Common stock total equity 5.00M 5.00M 5.00M 5.00M 5.00M
Preferred stock total equity - - - - -
Retained earnings total equity 8668.00M 7186.00M 5659.00M 4427.00M 3270.00M
Treasury stock -4539.00000M -2952.00000M -2230.00000M -2042.00000M -1487.00000M
Accumulated amortization - - - - -
Non currrent assets other 147.00M 111.00M 106.00M 98.00M 94.00M
Deferred long term asset charges - - - 88.00M 61.00M
Non current assets total 7419.00M 6970.00M 6998.00M 6797.00M 6378.00M
Capital lease obligations 186.00M 151.00M 163.00M 164.00M -
Long term debt total 6552.00M 6592.00M 6595.00M 5947.00M 6443.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -883.00000M 32.00M -27.00000M 138.00M 28.00M
Change to liabilities -111.00000M 185.00M 255.00M 73.00M 160.00M
Total cashflows from investing activities -883.00000M -458.00000M -572.00000M -504.00000M -2259.00000M
Net borrowings 1340.00M -604.00000M 732.00M -9.00000M 1493.00M
Total cash from financing activities -904.00000M -1862.00000M 123.00M -951.00000M 533.00M
Change to operating activities -47.00000M 195.00M 40.00M 32.00M 81.00M
Net income 2111.00M 2034.00M 1636.00M 1500.00M 1424.00M
Change in cash 96.00M -119.00000M 1670.00M 332.00M 38.00M
Begin period cash flow 3485.00M 3604.00M 1934.00M 1602.00M 1564.00M
End period cash flow 3581.00M 3485.00M 3604.00M 1934.00M 1602.00M
Total cash from operating activities 1912.00M 2213.00M 2126.00M 1795.00M 1790.00M
Issuance of capital stock - - - - -
Depreciation 465.00M 448.00M 441.00M 412.00M 308.00M
Other cashflows from investing activities -311.00000M -13.00000M -92.00000M -182.00000M -1949.00000M
Dividends paid -611.00000M -474.00000M -380.00000M -314.00000M 243.00M
Change to inventory -486.00000M -366.00000M -346.00000M -104.00000M 61.00M
Change to account receivables -137.00000M -155.00000M 74.00M -69.00000M -67.00000M
Sale purchase of stock -1594.00000M -743.00000M -250.00000M -626.00000M -698.00000M
Other cashflows from financing activities 1311.00M -6.00000M 9.00M -11.00000M 1474.00M
Change to netincome -82.00000M 71.00M 137.00M 31.00M -57.00000M
Capital expenditures 586.00M 477.00M 453.00M 460.00M 338.00M
Change receivables -137.00000M -155.00000M 74.00M -69.00000M -67.00000M
Cash flows other operating 152.00M -4.00000M -71.00000M -48.00000M -39.00000M
Exchange rate changes - - - -8.00000M -26.00000M
Cash and cash equivalents changes 125.00M -107.00000M 1677.00M 332.00M 38.00M
Change in working capital -699.00000M -343.00000M -85.00000M -151.00000M 112.00M
Stock based compensation 62.00M 58.00M 59.00M 67.00M 53.00M
Other non cash items 259.00M 96.00M 137.00M 46.00M 5.00M
Free cash flow 1326.00M 1736.00M 1673.00M 1335.00M 1452.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZTS
Zoetis Inc		 -2.975 1.78% 164.03 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.12 0.42% 28.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.925 1.33% 142.50 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.07 0.53% 13.04 32.67 11.53 0.01 0.87 0.02 0.07
TKPHF
Takeda Pharmaceutical Co. Ltd.		 - -% 25.38 32.60 11.59 0.01 0.88 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Inc

10 Sylvan Way, Parsippany, NJ, United States, 07054

Key Executives

Name Title Year Born
Ms. Kristin C. Peck CEO & Director 1971
Mr. Wetteny N. Joseph Exec. VP & CFO 1972
Ms. Heidi C. Chen Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics 1967
Mr. Glenn C. David Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices 1972
Ms. Roxanne Lagano Exec. VP and Chief HR Officer & Global Operations 1965
Ms. Wafaa Mamilli EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health 1967
Mr. Steven Frank VP of Investor Relations NA
Mr. William Price VP & Chief Communications Officer NA
Dr. Robert J. Polzer Ph.D. Exec. VP and Pres of R&D 1969
Ms. Jeannette Ferran Astorga Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.